USP General Chapter 797 exempts immediate-use compounded sterile preparations, CSPs prepared for direct, urgent administration to a single patient, from the facility, environmental, and testing requirements that apply to every other category of sterile compounding. The exemption in Section 1.3 Immediate-Use CSPs only applies when every one of its conditions holds at once. California's State Board of Pharmacy has told licensees that the provision is not meant to serve as a standard practice for compounding nonemergent sterile preparations outside the facility and testing requirements the chapter otherwise sets, and has urged pharmacies to review their compounding practices for compliance.
The Scope of the Immediate-Use Exception
The provision does not require that the need qualify as an emergency; it applies whenever every condition in Section 1.3 is met, regardless of the clinical setting. USP revised the chapter effective November 1, 2023, widening the window for beginning administration from one hour to four hours; the provision's separate limit of up to three different sterile products in a single preparation did not change. The provision lives inside USP 797/800's sterile-compounding chapter. It has no counterpart in the FDA's 503A/503B framework, and compounding ahead of a specific patient's need falls outside the provision no matter how fast the dose later reaches someone. For how that framework applies to a particular pharmacy's facility type, see 503A vs 503B: Which Framework Governs Your Compounding.
The Conditions That Must All Be Met
Section 1.3 lists several conditions, and the compounding has to satisfy each one, not just the ones that are convenient for a given shift. Administration must begin within four hours of the start of preparation, the provision's own beyond-use date, or the preparation must be discarded. The preparation cannot involve more than three different sterile products. Personnel preparing it must be trained and demonstrate competency in aseptic technique under the facility's own written procedures, with no fixed retraining interval set by the chapter itself. And unless the person who prepared the dose administers it directly, or witnesses its administration, the dose has to be labeled before it leaves their hands.
Where Inspectors Find the Workaround
The 2023 revision lets compounders prepare immediate-use doses in a single batch intended for more than one patient, something earlier versions of the chapter did not clearly permit. That change is where the misuse starts. A batch prepared for a full shift's anticipated patients is not the same as a dose prepared for one patient's immediate need, and every dose in that batch still has to meet its own four-hour window, its own three-product limit, and its own labeling requirement. A compounding record is required once an immediate-use batch is intended for more than one patient. Doses held past four hours, or an immediate-use designation used to avoid the cleanroom and testing requirements that would otherwise apply, fall outside the exception and must instead meet the facility, personnel, and testing requirements for Category 1, Category 2, or Category 3 preparations.
The immediate-use exception excuses a pharmacy from Chapter 797's facility and testing requirements. It does not excuse the pharmacy from any single one of Section 1.3's own conditions.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a state board inspection finding, an FDA Form 483, or any other inquiry tied to immediate-use compounding. Early legal intervention can protect the pharmacy's rights, ensure an accurate and complete response to the inspection, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with the board or agency on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to license action that proper handling could have avoided.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacies through USP 797 and USP 800 inspection findings, FDA Form 483 responses, and the state board license defense that can follow either one.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
If a state board of pharmacy has cited an immediate-use finding, or opened any inspection into a compounding practice's sterile preparations, contact Health Law Alliance's compounding pharmacy attorneys for a free, confidential consultation before the response window closes.
